SP263、SP142 和 22C3 抗体在膀胱尿路上皮癌中的 PD-L1 免疫组化表达:比较研究

IF 1.5 4区 医学 Q3 PATHOLOGY
Panagiotis Paliogiannis , Renato Lobrano , Michele Angelo Bella , Antonella Fara , Maria Gabriela Uras , Maria Antonia Pinna , Alessandro Tedde , Massimo Madonia , Angelo Zinellu , Antonio Cossu
{"title":"SP263、SP142 和 22C3 抗体在膀胱尿路上皮癌中的 PD-L1 免疫组化表达:比较研究","authors":"Panagiotis Paliogiannis ,&nbsp;Renato Lobrano ,&nbsp;Michele Angelo Bella ,&nbsp;Antonella Fara ,&nbsp;Maria Gabriela Uras ,&nbsp;Maria Antonia Pinna ,&nbsp;Alessandro Tedde ,&nbsp;Massimo Madonia ,&nbsp;Angelo Zinellu ,&nbsp;Antonio Cossu","doi":"10.1016/j.anndiagpath.2024.152267","DOIUrl":null,"url":null,"abstract":"<div><p><span>Programmed death ligand 1<span> (PD-L1) is currently the only biomarker used for the selection of patients with bladder<span><span> urothelial cancer<span> for immunotherapy. Several platforms, antibodies and scores are currently available for the evaluation of the expression of PD-L1 in </span></span>immunohistochemistry<span> (IHC). In this study three different antibodies (SP263, SP142 and 22C3) were compared to establish their performances and concordance rates. Twenty-four consecutive cases of surgically resected urothelial cancers of the bladder were enrolled. All cases were revised, and appropriate tumor areas were selected for IHC. Three commercially available PD-L1 antibodies were tested: 22C3 pharmDx with Dako Autostainer Link 48 (Dako, Carpinteria, Ca), and SP263 and SP142 with the Ventana BenchMark (Ventana Medical Systems, Tucson, AZ) platform. All slides were evaluated by an expert pathologist and both the tumor proportion score (TPS) and the combined positive score (CPS) were determined and compared at two different cut-off levels (≥ 1 and ≥ 10). The SP263 and 22C3 clones produced more positive results with the CPS and TPS scores, respectively. The CPS score identified more positive cases than the TPS score, irrespectively of the clone or the cut-off used; the difference was statistically significant in both the SP263 and SP142 clones with the ≥1 cut-off. No statistically significant differences were found between the clones when the ≥1 cut-off was used, irrespectively of the score. At the contrary, a statistically significant difference (</span></span></span></span><em>p</em> = 0.024) and a trend to significance (<em>p</em> = 0.082) were respectively found for the TPS and CPS scores, when the SP22C3 and the SP142 clones were compared at a cut-off level of ≥10. The ICC test using CPS was 0.676 and 0.578 for the ≥1 and ≥ 10 cut-offs respectively, and 0.729 and 0.467 respectively for the same cut-offs using TPS. This suggests that the three antibodies under investigation cannot be used interchangeably, especially the 22C3 and SP142 clones which showed statistically significant difference when TPS was tested at a ≥ 10 cut-off.</p></div>","PeriodicalId":50768,"journal":{"name":"Annals of Diagnostic Pathology","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2024-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"PD-L1 immunohistochemical expression in bladder urothelial cancer with SP263, SP142 and 22C3 antibodies: A comparative study\",\"authors\":\"Panagiotis Paliogiannis ,&nbsp;Renato Lobrano ,&nbsp;Michele Angelo Bella ,&nbsp;Antonella Fara ,&nbsp;Maria Gabriela Uras ,&nbsp;Maria Antonia Pinna ,&nbsp;Alessandro Tedde ,&nbsp;Massimo Madonia ,&nbsp;Angelo Zinellu ,&nbsp;Antonio Cossu\",\"doi\":\"10.1016/j.anndiagpath.2024.152267\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p><span>Programmed death ligand 1<span> (PD-L1) is currently the only biomarker used for the selection of patients with bladder<span><span> urothelial cancer<span> for immunotherapy. Several platforms, antibodies and scores are currently available for the evaluation of the expression of PD-L1 in </span></span>immunohistochemistry<span> (IHC). In this study three different antibodies (SP263, SP142 and 22C3) were compared to establish their performances and concordance rates. Twenty-four consecutive cases of surgically resected urothelial cancers of the bladder were enrolled. All cases were revised, and appropriate tumor areas were selected for IHC. Three commercially available PD-L1 antibodies were tested: 22C3 pharmDx with Dako Autostainer Link 48 (Dako, Carpinteria, Ca), and SP263 and SP142 with the Ventana BenchMark (Ventana Medical Systems, Tucson, AZ) platform. All slides were evaluated by an expert pathologist and both the tumor proportion score (TPS) and the combined positive score (CPS) were determined and compared at two different cut-off levels (≥ 1 and ≥ 10). The SP263 and 22C3 clones produced more positive results with the CPS and TPS scores, respectively. The CPS score identified more positive cases than the TPS score, irrespectively of the clone or the cut-off used; the difference was statistically significant in both the SP263 and SP142 clones with the ≥1 cut-off. No statistically significant differences were found between the clones when the ≥1 cut-off was used, irrespectively of the score. At the contrary, a statistically significant difference (</span></span></span></span><em>p</em> = 0.024) and a trend to significance (<em>p</em> = 0.082) were respectively found for the TPS and CPS scores, when the SP22C3 and the SP142 clones were compared at a cut-off level of ≥10. The ICC test using CPS was 0.676 and 0.578 for the ≥1 and ≥ 10 cut-offs respectively, and 0.729 and 0.467 respectively for the same cut-offs using TPS. This suggests that the three antibodies under investigation cannot be used interchangeably, especially the 22C3 and SP142 clones which showed statistically significant difference when TPS was tested at a ≥ 10 cut-off.</p></div>\",\"PeriodicalId\":50768,\"journal\":{\"name\":\"Annals of Diagnostic Pathology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2024-01-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Diagnostic Pathology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1092913424000042\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PATHOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Diagnostic Pathology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1092913424000042","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PATHOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

程序性死亡配体 1(PD-L1)是目前用于选择膀胱尿路上皮癌患者接受免疫疗法的唯一生物标记物。目前有多种平台、抗体和评分方法可用于评估免疫组化(IHC)中 PD-L1 的表达。本研究比较了三种不同的抗体(SP263、SP142 和 22C3),以确定它们的性能和一致性。研究对象为 24 例连续手术切除的膀胱尿路上皮癌患者。对所有病例进行修订,并选择适当的肿瘤区域进行 IHC 检测。检测了三种市售的 PD-L1 抗体:使用 Dako Autostainer Link 48 (Dako, Carpinteria, Ca) 的 22C3 pharmDx,以及使用 Ventana BenchMark (Ventana Medical Systems, Tucson, AZ) 平台的 SP263 和 SP142。所有切片均由病理专家进行评估,确定肿瘤比例评分(TPS)和综合阳性评分(CPS),并在两种不同的截断水平(≥ 1 和≥ 10)下进行比较。SP263 和 22C3 克隆的 CPS 和 TPS 评分分别产生了更多的阳性结果。无论克隆或使用的截断值如何,CPS 评分比 TPS 评分识别出更多的阳性病例;在 SP263 和 SP142 克隆中,截断值≥1 的差异具有统计学意义。在使用≥1分界值时,无论得分高低,克隆之间的差异都没有统计学意义。相反,当 SP22C3 和 SP142 克隆的 TPS 和 CPS 分值以≥10 为临界值进行比较时,分别发现了具有统计学意义的差异(p = 0.024)和显著性趋势(p = 0.082)。使用 CPS 进行 ICC 检验,≥1 和≥10 临界值分别为 0.676 和 0.578,使用 TPS 进行相同临界值分别为 0.729 和 0.467。这表明,所研究的三种抗体不能互换使用,尤其是 22C3 和 SP142 克隆,当 TPS 在≥10 截断点进行测试时,它们的差异具有统计学意义。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
PD-L1 immunohistochemical expression in bladder urothelial cancer with SP263, SP142 and 22C3 antibodies: A comparative study

Programmed death ligand 1 (PD-L1) is currently the only biomarker used for the selection of patients with bladder urothelial cancer for immunotherapy. Several platforms, antibodies and scores are currently available for the evaluation of the expression of PD-L1 in immunohistochemistry (IHC). In this study three different antibodies (SP263, SP142 and 22C3) were compared to establish their performances and concordance rates. Twenty-four consecutive cases of surgically resected urothelial cancers of the bladder were enrolled. All cases were revised, and appropriate tumor areas were selected for IHC. Three commercially available PD-L1 antibodies were tested: 22C3 pharmDx with Dako Autostainer Link 48 (Dako, Carpinteria, Ca), and SP263 and SP142 with the Ventana BenchMark (Ventana Medical Systems, Tucson, AZ) platform. All slides were evaluated by an expert pathologist and both the tumor proportion score (TPS) and the combined positive score (CPS) were determined and compared at two different cut-off levels (≥ 1 and ≥ 10). The SP263 and 22C3 clones produced more positive results with the CPS and TPS scores, respectively. The CPS score identified more positive cases than the TPS score, irrespectively of the clone or the cut-off used; the difference was statistically significant in both the SP263 and SP142 clones with the ≥1 cut-off. No statistically significant differences were found between the clones when the ≥1 cut-off was used, irrespectively of the score. At the contrary, a statistically significant difference (p = 0.024) and a trend to significance (p = 0.082) were respectively found for the TPS and CPS scores, when the SP22C3 and the SP142 clones were compared at a cut-off level of ≥10. The ICC test using CPS was 0.676 and 0.578 for the ≥1 and ≥ 10 cut-offs respectively, and 0.729 and 0.467 respectively for the same cut-offs using TPS. This suggests that the three antibodies under investigation cannot be used interchangeably, especially the 22C3 and SP142 clones which showed statistically significant difference when TPS was tested at a ≥ 10 cut-off.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
3.90
自引率
5.00%
发文量
149
审稿时长
26 days
期刊介绍: A peer-reviewed journal devoted to the publication of articles dealing with traditional morphologic studies using standard diagnostic techniques and stressing clinicopathological correlations and scientific observation of relevance to the daily practice of pathology. Special features include pathologic-radiologic correlations and pathologic-cytologic correlations.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信